Test Propionate 100mg/mL | 10-Vial
Short ester · ~2 day t½ · AR baseline
QSC Peptides · 100:100
$240Buy →
≥99% Pure · COA
The minimal-aromatization research combination: Testosterone Propionate (short-ester AR baseline), Trenbolone Acetate (5× potency, no aromatization, strong PR), Masteron Propionate (DHT + endogenous aromatase inhibitor), and Winstrol (pyrazole DHT, SHBG displacement). Four compounds with minimal estrogenic activity — studying AR-dominant physiology without E2 confounds.
Shop All QSC Steroids →QSC Peptides · 100:100
QSC Peptides · Highest potency
QSC Peptides · 62:25
QSC Peptides · 320:30
| Compound | Aromatizes | A:A Ratio | AI Activity | SHBG Effect |
|---|---|---|---|---|
| Test Propionate | Yes (minor at low dose) | 100:100 | No | Binds SHBG |
| Trenbolone Ace | No (Δ9,11) | 500:500 | No | Neutral |
| Masteron Prop | No + inhibits CYP19A1 | 62:25 | Yes (steroidal) | Moderate |
| Winstrol | No | 320:30 | No | Displaces (high affinity) |
This stack is designed for research into pure AR-mediated physiology without E2 confounds. Trenbolone does not aromatize due to its Δ9,11 double bonds. Masteron doesn't aromatize and actively inhibits CYP19A1 — reducing E2 from the minimal aromatization of Test Propionate. Winstrol contributes no estrogenic activity.
Masteron's unique aromatase inhibitor activity makes it function as a pharmacological tool within the stack — the compound simultaneously activates AR (62:25 ratio) and reduces E2 production from other compounds by inhibiting CYP19A1. This eliminates the need for a separate external AI compound in research designs requiring minimal estrogen.
Stanozolol's high SHBG affinity displaces other co-administered steroids from SHBG binding, increasing their free fraction. This makes the cutting stack pharmacologically interesting for studying how SHBG-displacement changes the effective free concentration of Testosterone Propionate and Trenbolone — enabling free-vs-bound research within a single protocol.